Tobacco use remains the single largest preventable cause of premature death globally, yet the vast majority of the world's 1.3 billion smokers live in low- and middle-income countries (LMICs) where access to proven cessation tools is severely limited. This review from the New England Journal of Medicine arrives at a critical inflection point: as high-income nations see smoking rates decline, the burden is shifting decisively southward, making the question of what actually works in resource-constrained settings both urgent and underexplored.
The NEJM review synthesizes available clinical and behavioral evidence for cessation interventions specifically evaluated or adapted for LMIC contexts. The analysis examines pharmacological options — including nicotine replacement therapy, varenicline, and bupropion — alongside behavioral support modalities such as brief physician counseling, mobile text-message programs, and community health worker-led interventions. The authors assess both efficacy data and real-world feasibility, addressing cost, supply chain reliability, and regulatory barriers that frequently undermine implementation even when evidence is strong. Key findings identify mobile-health (mHealth) platforms and low-cost brief counseling as particularly scalable, while highlighting that varenicline's efficacy advantage seen in high-income trials may not be reproducible where adherence and access bottlenecks are significant.
This review is editorially important because most cessation research has been conducted in North America, Europe, and Australia — populations whose healthcare infrastructure, nicotine product landscape, and socioeconomic contexts differ dramatically from LMICs. Translating that evidence without critical adaptation risks irrelevance. The NEJM's decision to dedicate a full review article to this gap signals growing recognition that global tobacco control cannot be achieved by exporting Western protocols wholesale. For health-conscious readers tracking longevity science, this matters because tobacco cessation at the population level remains the intervention with the highest proven life-years-gained per dollar — meaning better implementation in LMICs could produce outsized global longevity dividends. The review's limitations are inherent to the field: LMIC-specific cessation RCTs remain scarce, and much of the synthesized evidence is still extrapolated rather than generated locally.